Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of “Buy” from Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have earned an average recommendation of “Buy” from the eight ratings firms that are presently covering the stock, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have issued a report on the stock in the last year is $8.2857.

A number of research firms have recently weighed in on TSHA. Chardan Capital boosted their target price on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, August 12th. JMP Securities upped their price target on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the company a “market outperform” rating in a report on Thursday, May 29th. Wells Fargo & Company upped their price target on shares of Taysha Gene Therapies from $7.50 to $8.00 and gave the company an “overweight” rating in a report on Wednesday, August 13th. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a report on Thursday, May 29th. Finally, Bank of America initiated coverage on shares of Taysha Gene Therapies in a report on Friday, July 11th. They set a “buy” rating and a $8.00 price target on the stock.

Taysha Gene Therapies Stock Performance

Taysha Gene Therapies stock opened at $2.92 on Tuesday. The company’s 50-day moving average price is $2.67 and its 200-day moving average price is $2.22. Taysha Gene Therapies has a twelve month low of $1.05 and a twelve month high of $3.31. The company has a quick ratio of 12.48, a current ratio of 12.48 and a debt-to-equity ratio of 0.17. The company has a market cap of $796.58 million, a PE ratio of -8.59 and a beta of 0.98.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Tuesday, August 12th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). Taysha Gene Therapies had a negative return on equity of 78.44% and a negative net margin of 1,144.97%.The business had revenue of $1.99 million during the quarter, compared to the consensus estimate of $1.61 million. On average, equities research analysts forecast that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds have recently added to or reduced their stakes in the company. Hsbc Holdings PLC grew its holdings in Taysha Gene Therapies by 65.6% during the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock valued at $36,000 after purchasing an additional 8,076 shares during the last quarter. BNP Paribas Financial Markets bought a new position in Taysha Gene Therapies in the 4th quarter worth about $41,000. Millennium Management LLC bought a new position in Taysha Gene Therapies in the 4th quarter worth about $262,000. Barclays PLC grew its stake in Taysha Gene Therapies by 35.6% in the 4th quarter. Barclays PLC now owns 335,238 shares of the company’s stock worth $587,000 after acquiring an additional 87,958 shares in the last quarter. Finally, Ameriprise Financial Inc. bought a new position in Taysha Gene Therapies in the 4th quarter worth about $40,000. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.